Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sansero Life Sciences","sponsor":"University of Toronto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sansero Life Sciences

    Menu

    Sansero Life Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sansero Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications

              Details:

              The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and how low-dose psilocybin affects mental health conditions such as depression and anxiety.

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: University of Toronto

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY